AngioDynamics (NASDAQ:ANGO) Shares Cross Above 200-Day Moving Average – Time to Sell?

AngioDynamics, Inc. (NASDAQ:ANGO) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $10.91 and traded as high as $13.25. AngioDynamics shares last traded at $12.87, with a volume of 228,939 shares changing hands.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Wall Street Zen downgraded AngioDynamics from a “buy” rating to a “hold” rating in a research note on Sunday, December 21st. Canaccord Genuity Group upped their target price on AngioDynamics from $17.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, October 3rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a report on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, AngioDynamics presently has a consensus rating of “Moderate Buy” and an average target price of $19.33.

AngioDynamics Stock Performance

The firm’s 50 day moving average is $12.65 and its 200-day moving average is $10.94. The stock has a market capitalization of $529.01 million, a price-to-earnings ratio of -16.46 and a beta of 0.49.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.02. The company had revenue of $75.71 million for the quarter, compared to analyst estimates of $72.69 million. AngioDynamics had a negative net margin of 10.67% and a negative return on equity of 3.16%. The firm’s revenue was up 12.1% on a year-over-year basis. During the same quarter last year, the business earned ($0.11) earnings per share. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS. As a group, sell-side analysts forecast that AngioDynamics, Inc. will post -0.37 earnings per share for the current year.

Insider Transactions at AngioDynamics

In other AngioDynamics news, CEO James C. Clemmer bought 10,000 shares of AngioDynamics stock in a transaction dated Thursday, October 9th. The stock was acquired at an average cost of $11.15 per share, with a total value of $111,500.00. Following the purchase, the chief executive officer directly owned 882,529 shares in the company, valued at $9,840,198.35. This represents a 1.15% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Lawrence T. Weiss bought 10,000 shares of the firm’s stock in a transaction dated Tuesday, October 21st. The shares were acquired at an average price of $11.81 per share, for a total transaction of $118,100.00. Following the transaction, the senior vice president directly owned 93,597 shares in the company, valued at approximately $1,105,380.57. This represents a 11.96% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 20,890 shares of company stock valued at $239,532 in the last ninety days. 6.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On AngioDynamics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Divisadero Street Capital Management LP increased its stake in shares of AngioDynamics by 253.7% during the second quarter. Divisadero Street Capital Management LP now owns 3,395,430 shares of the medical instruments supplier’s stock worth $33,683,000 after purchasing an additional 2,435,365 shares in the last quarter. UBS Group AG boosted its stake in shares of AngioDynamics by 83.6% in the third quarter. UBS Group AG now owns 1,102,488 shares of the medical instruments supplier’s stock worth $12,315,000 after acquiring an additional 501,881 shares during the last quarter. Millennium Management LLC increased its position in shares of AngioDynamics by 28.1% during the third quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock worth $20,030,000 after purchasing an additional 393,682 shares in the last quarter. Bastion Asset Management Inc. increased its position in shares of AngioDynamics by 31.8% during the third quarter. Bastion Asset Management Inc. now owns 1,264,003 shares of the medical instruments supplier’s stock worth $13,442,000 after purchasing an additional 304,960 shares in the last quarter. Finally, Trexquant Investment LP raised its stake in AngioDynamics by 334.2% in the 1st quarter. Trexquant Investment LP now owns 355,066 shares of the medical instruments supplier’s stock valued at $3,334,000 after purchasing an additional 273,295 shares during the last quarter. 89.43% of the stock is owned by hedge funds and other institutional investors.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.